Calico Life Sciences LLC

Contents

1. 🔬 Origins & History
2. 🧬 Research Focus
3. 🌟 Collaborations & Partnerships
4. 🔮 Future Directions
5. Frequently Asked Questions
6. Related Topics

Overview

Calico Life Sciences LLC was founded in 2013 by Arthur Levinson, former CEO of Genentech, with backing from Google. The company's mission is to understand the biology of aging and develop interventions to improve human health. Calico's research focuses on the underlying mechanisms of aging, including cellular senescence, epigenetics, and the role of genetics in aging. Companies like Google, through its subsidiary Verily Life Sciences, and pharmaceutical giants like Pfizer, have been investing heavily in aging research, with the goal of developing new therapies to treat age-related diseases. Researchers like David Sinclair, a professor at Harvard University, and Cynthia Kenyon, a molecular biologist at the University of California, San Francisco, have made significant contributions to the field of aging biology.

🧬 Research Focus

Calico's research approach is interdisciplinary, combining expertise from biology, chemistry, physics, and computer science to tackle the complex challenges of aging. The company has assembled a team of renowned scientists, including Dr. Cynthia Kenyon, a molecular biologist who has made significant contributions to the understanding of aging in C. elegans, and Dr. David Botstein, a geneticist who has developed innovative approaches to understanding the genetics of aging. Calico has also partnered with institutions like the University of California, San Francisco, and the Broad Institute of MIT and Harvard to advance its research goals. Companies like Illumina, a leading provider of genetic sequencing technologies, and Biogen, a biotechnology company focused on neurodegenerative diseases, have also collaborated with Calico on various research projects.

🌟 Collaborations & Partnerships

Calico has established collaborations with leading research institutions and companies to advance its research goals. The company has partnered with the University of California, San Francisco, to develop new therapies for age-related diseases, and with the Broad Institute of MIT and Harvard to apply cutting-edge genomics and computational approaches to aging research. Calico has also collaborated with companies like AbbVie, a pharmaceutical company focused on developing new treatments for age-related diseases, and with the Buck Institute for Research on Aging, a leading research institution dedicated to understanding the biology of aging. Researchers like Eric Kandel, a Nobel laureate and professor at Columbia University, and Elizabeth Blackburn, a Nobel laureate and professor at the University of California, San Francisco, have also contributed to Calico's research efforts.

🔮 Future Directions

As Calico continues to advance its research, the company is poised to make significant contributions to the field of aging biology. With its long-term approach to research and its commitment to understanding the underlying mechanisms of aging, Calico is well-positioned to develop innovative therapies to improve human healthspan. The company's research has the potential to impact a wide range of age-related diseases, from cancer and cardiovascular disease to neurodegenerative disorders like Alzheimer's and Parkinson's. Companies like Amazon, through its subsidiary Amazon Web Services, and Microsoft, have also been investing in aging research, with the goal of developing new technologies to support healthy aging. Researchers like George Church, a professor at Harvard University, and Jennifer Doudna, a professor at the University of California, Berkeley, have been exploring the potential of gene editing technologies like CRISPR to treat age-related diseases.

Key Facts

Year

2013

Origin

United States

Category

science

Type

organization

Frequently Asked Questions